期刊文献+

中西医结合治疗慢性粒细胞白血病进展 被引量:3

Review on CML Treated with Combination of TCM and WM
下载PDF
导出
摘要 近年来,慢性粒细胞白血病(CML)中西医的治疗在以往的基础上有了长足的进展,针对BCR-ABL酪氨酸激酶开发抑制剂是CML靶向治疗的重点,骨髓移植是治疗CML最理想的方法,同时随着对CML信号传导途径的深入研究,个体化治疗也将成为可能。而中医对本病各家认识不一,但都不离虚、毒,瘀三个环节。 In recent years,CML treated with combination of TCM and WM has got great achievement on the basis of before. Pointing to the emphasis that the inhibitor of BCR-ABL tyrosine kinases is the target treatment of CML,marrow transplantation is the most ideal method for CML meanwhile,with further research on CML signal transmitting route,individualized treatment will be possible. Though every expert has his own idea to the disease from TCM,it still concerns 3 links of deficiency,toxin and stasis.
出处 《浙江中医药大学学报》 CAS 2008年第3期417-418,共2页 Journal of Zhejiang Chinese Medical University
关键词 慢性粒细胞白血病 羟基脲 分子靶向 造血干细胞移植 中医药治疗 综述 CML hydroxyacrbamide molecular target transplantation of blood-producing dry cell TCM therapy review
  • 相关文献

参考文献11

二级参考文献34

  • 1陈姝,娄世锋,罗云,陈林,周慷.拓扑替康为主联合方案治疗难治急性髓系白血病的临床观察[J].重庆医学,2005,34(10):1483-1484. 被引量:1
  • 2万岁桂,钱林生,米桂祥,薛艳萍,竺晓凡,赵耀中,杨德光,张薇.基因重组α干扰素治疗48例慢性粒细胞白血病的临床观察[J].中华血液学杂志,1996,17(7):344-347. 被引量:16
  • 3张之南 刘尔坤 等.中西药长期轮替治疗CML的远期疗效观察[J].中国中西医结合杂志,1985,5(2):80-80.
  • 4Deininger MWN, Vieira S, Mendiola R, et al. bcr-abl tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia[J]. Cancer Res, 2000, 60:2049 -2055.
  • 5O' Dwyer M E, Mauro M J, Druker B J. Recent advancements in the treatment of chronic myelogenous leukemia[J]. Annu Rev Med, 2002,53:369-381.
  • 6Porosnicu M, Nimmanapalli R, Nguyen D, et al. Co- treatment with As2O3 enhances selective cytotoxic effects of STI-571 against bcr-ablpositive acute leukemia cells[J]. Leukemia, 2001, 15:772-778.
  • 7La Rosee P, Johnson K, O'Dwyer M E, et al. In vitro studies of the combination of imatinib mesylate (Gleevec)> and arsenic trioxide (Trisenox) in chronic myelogenous leukemia[J]. Exp Hematol, 2002,30:729 -737.
  • 8Wadhwa J, Szydlo R M, Apperley J F, et al. Factors affecting duration of survival after onset of blastic trans-formation of chronic myeloid leukemia. Blood, 2002,99:2304-2309.
  • 9Deininger M W, Golderman J M, Lydon N, et al. The tyrosine kinase inhibitor CGP571 48B selectively inhibits the growth of BCR-ABL positive cells. Blood, 1997,90:3691-3698.
  • 10Champlin R, Khouri I, Shimoni A, et al. Harnessing graft versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation,an evolving strategy for adoptive immunotherapy. Br J Haematol, 2000, 111:18-29.

共引文献51

同被引文献34

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部